is a heterogeneous condition marked by a number of different immmlogic defects. One group of patients, perhaps 60% of the CVI group as a whole, is characterized by T cells that produce reduced amounts of IG2 (mRNA and protein product), IG4, and IL-5 (mRNA) when stimulated with phytohemagglutinin. This defect does not extend to all lymphokines, however, because the cells produce normal amounts of interferony (mRNA and protein product) when exogenous IG2 is present. Recently, we have reexamined the T cell lymphokine prodaction defect using a panoply of T-cell activation stimuli and have shown that the defect is a subtle one that depends on activation of the cell via the CD3-T-cell receptor complex. Because T cells proliferate normally when stimulated via this receptor, this finding suggests the presence of a "downstream" defect, perhaps one involving the factors that are necess~ry for activation of lymphokine genes. A second form of CVI, in this case involving approximately 30% of the CVI group as a whole, is characterized by a reduced CD41CWI ratio and elevated numbers of CWI+ T cells bearing the CD57 marker. Although the CD4+ T cells in this patient group elaborate normal amounts of IL-2 under various activation conditions, their CWI+ T cells produce hmased amounts of interfern. Furthermore, the CD8+ T cells in this case act as "suppressor" T cells, which suppress IgG production but not IgM production of pnrified (normal) SAC+, IL-2-induced B cells. These "CD8Lm CVI patients display lymphocyte phenotype markers that are similar to those of patients with chronic viral infthus, it is possible that they have an immdefdency resulting from a s~~btle infection that resalts in the development of T cells capable of down-regulating B-ceU responses. Overall, these studies allow a better defmition of CVI and suggest potential lympholiae-based therapies of selected patients.
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(Pufiatr Ru 33 (Suppl): S24-S28,1993) Abbreviations CVI is a heterogeneous group of disorders characterized by hypogammaglobulinemia and recurrent infection (1) . In the 1970s and 1980% numerous in vitro studies of CVI patients' mononuclear cells were performed using increasingly purified cell populations and increasingly defined methods of cell stimulation to characterize the cellular defect in this disease (2-6). A general result of these studies was that, whereas CVI T cells provided normal help to (allogeneic) B cells in assays of in vitro Ig synthesis, CVI B cells could not be helped by (allogeneic) normal T cells. In addition, whereas some patients manifested abnormally increased s u p p m r T d activity, the latter was usually associated with B cells that do not perform normally in vitro after enrichment and coculture with normal T cells. Overall, these tindings led to the view that CVI is largely, if not totally, due to an abnormality of B cells. More recently, however, several studies have appeared that show that CVI T cells do not function in a completely normal fashion and that these patients' B cells do not function in a completely abnormal fashion (2, 7-10). In these studies, it was found that mitogen-induced T-cell proliferation and IL2 production in the CVI patient population as a whole are reduced and that CVI patient B cells frequently produce respectable amounts of IgM (but not IgG or IgA) when stimulated in vitro (3, 7, 10-12). These studies reopened the question of whether T cells in CVI patients are normal and set the stage for our own studies of CVI, which had, as a goal, the measurement of the capacity of CVI T cells to produce various lymphokines.
CVI PATIENTS WITH NORMAL T C E U PHENOTYPES
In our initial studies, we focused on the CVI patients with normal T-cell phenotypes, who constitute about two thirds of patients with CVI. In particular, we studied patients who exhib ited normal numbers of CD4+ and CD8+ T cells as well as a normal proportion of CD4SR4-bearing T cells. This last point is important because it is now quite clear that CD4SRA-and CIXSRO-bearing T cells (so-called naive and memory T cells, respectively) have different lymphokine production profiles, so that a change in the CD45RA/RO ratio could be a relatively trivial cause of a lymphokine production abnormality (13). In addition, these patients had normal PHA-induced proliferation values, indicating that any lymphokine production defect, if pment, could not be the result of an abnormality of T-cell growth.
In a typical study, we determined the capacity of peripheral blood mononuclear cells (containing CD4+ and CD8+ T cells) stimulated by the Toell mitogen PHA to produce IL2, IL-4, IL 5, FWy, and IG2Ra mRNA using the RNA slot-blot technique. As shown in F i g u n 1, patient T cells produced about 10 to 40% as much IG2 mRNA as normal T cells, in addition, they produced decreased amounts of L-4 and IL5 mRNA. The IG 2 mRNA production deficiency was accompanied by an abnormality of IL2 secretion as assessed by ELISA of IG2 secretion into culture supematants.
These findings contrasted somewhat with those relating to IG 2Ra and IFN--y mRNA production. First, T-cell IG2Ra production, as measured both by mRNA expression in slot blots and by cell surface expression (CD25), was completely normal.
Second, whereas IFNr mRNA production was normal at 6 h that the lymphokine production abnormality in this ! CVI patients is specific for the TCR-CD3 activation ' . and that other signaling pathways (e.g. the CD28 path-? Wy) aie intact, As such, it is reminiscent of an earlier finding made with whole T d populations in which costimulation with ~~a a t a t e w a s a M e t o n a n a s l i a c I G 2~n
P a r i p b a a l b b o d~~~~s t i m~w i t h P H A , a n d t o t a l
by PHA-stimulated T cells (16) .
Overall, these studies show rather unequivocally that a ' subgroup of CVI patients has a partial, but nonetheless definite, lymphokine production defect. This defect is unlikely to be one an explanation for the fact that FI+y production is i n t w beeause the DNA fhcto~s necessary for IFNy mRNA productim 2 ane not coextensive with those necess;cry for IL-2 mRNA p~o.
duction. Along these lines, the normal rmpollse of patient oedlrto mtLCD28 is explainable in that the IG2 gene has an enhancstregion that relates to CD28 signaling independently of enhancer regions relating to CD3 sigaaling (1 7).
CVI PATIENTS WITH ABNORMAL T-CELL PHENOTYPES: T D 8 Y "
In subsequent studies, we investigated the immunologic defect in a second gmup of patients with CVI, those with abnormal Tcell phenotypaa This group of patients constitutes a quarter to a third of all CVf patients and is marked by the presence of an elevated number of CD8+ T cells and a low CD4/CD8 T-cell miio (18 IFWyandIG5ascompandtoawnmalumtrdCD8+T-~ell population; in addition, CD8+ T d production of IL4 was also increased, but in this case, to a n -t extent. Thus, although the CD8+ T alls in CD8' patients are relatively unreactive to prolifmtive stimuli, they nevertheless produce increased amounts of certain lymphokines. The data on CD8+ T-cell lymphokine production M b e d above suggested that these T cells are highly differentiated "effector-type" T cells. To explore this &bility, we measured the ~~~t y o f C D 8 + T c e l l s t o a c t a~s u~r T c e b a n d~x i c T cells. In initial studies directed at suppressor T a l l activity, we performed studies to determine the capacity of 0 8 " patients' CD8+ T cells to affect Ig production by SAC-induced allogeneic tonsillar B cells. We found, somewhat to our surprise, that whereas CD8+ T cells from CD8" patients had little effect on normal B cell IgM production, they had a pronounced and cell dose-dependent inhibitory effect on IgG production. Thus, these cells affect the differentiation of normal B cells in vitro, either at the level of the isotype switch differentiation or the level of terminal differentiation.
In additional studk, we investigated the cytotoxic -ties of CD8+ T cells from CD8' patients and showed that such cells Having estabhhed that CD8+ T cells in CD8' patients had both suppnssor and cytolytic functions, we investigated the 1 possible role of these cells in the patients' hypogammaglobulinemia. First, we determined the capacity of highly purified B cells from CD8' CVI patients to produce Ig under SAC stimulation in the presence of L 2 . The 
SUMMARY
The above studies allow us to define two very diffmnt CVI patient populations. The first patient group is cham&hd a normal T-cell phenotype and T cells (a+ T cells) thaf have a partial abnormality of lymphokine production. The si@l~a~lce of this T -c e l l abnormality to the patients' hhypogam~obbli-nemia is uncertain. On the one hand, it is pWiMc that the -t y is a primary factor in the accompanying B-cell defect and is capable of causing a subtle but critical block in B-cell ckvclopment leading to in vivo and in vitro Ball u-nsivencsa In this view, the function of patient B cells in culture is not indicative of an intrinsic B-cell defect, but rather a developmental defect secondary to the demonstrable T-cell lymphokine production abn-.
On the other hand, it is also possible that the T a l l defect is one that is independent of the Ece11 defect and that the latter is a primary factor in disease pathogemsis In this context, it is possible that this form of CVI is caused by a common intracellular defect that independently causes an abnormality of lymphokine production in T cells and of Ig produe tion in B cells.
The second patient group, CD8' CVI, is characterized by an abnormal T-cell phenotype and CD8+ T cells that m d e s t abnormalities of proliferation and lymphokine production. In this case, we again cannot clearly e@ablish a role for the T cells in the causation of the accompanying B-cell abnormality, except in the occasional patient, although it remains possible that such a role exists. In this case, we are impressed with the fact that the patients mm8est a T d profile that is similar to that found in persistent viral infection, and it is thus worth considering the possibility that this form of CVI is due to a subtle and chronic infection that is the proximal cause of the B-cell dysfunction. The development of CD8+ T cells is then a secondary phenomenon and not the cause of the hypogammaglobulinemia.
Overall, the studies presented here provide a new way to organize CVI into more coherent pathophysiologic groups. In addition, the studies begin to provide a molecular explanation of the disease and suggest important leads as to the direction of future lwcarch.
